



# Session 12: Future for AMR Surveillance

## Outputs of previous discussions on objectives and priorities for AMR surveillance

Ole Heuer, Surveillance Section  
European Centre for Disease Prevention and Control

Joint Annual Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI)  
Networks, Warsaw, Poland, 23-25 November, 2011

# Previous discussions on objectives and priorities for AMR surveillance

Notes and working group feedback from:

- EARS-Net Coordination Group meeting, March 2010 (2 hour discussion on **future challenges for AMR surveillance**)
- EARS-Net Annual Meeting, November 2010 (3 discussion groups on **future objectives and priorities**)

# Future challenges for AMR surveillance in Europe (1)

- **International spread** of AMR
- Possible **reservoirs for AMR** import to Europe
  - Transport routes of food
  - Migration of people & food from and outside Europe
- **Absence of coordinated AMR** surveillance activities in many countries outside Europe
- The **need for collaboration** between international organizations (e.g. WHO, EFSA, ECDC) on AMR
- The need for a **holistic approach** (involving data from animals and food) to control AMR
- To **combine data** on AB consumption with AMR

# Future challenges for AMR surveillance in Europe (2)

- **Getting better** at what we are already doing **versus** **increasing the scope** of surveillance
- **Improve the national participation** in EARS-Net
- **Identify new and emerging threats** with the existing structure?



# AMR surveillance priorities

## Short/medium term

Stabilise reporting system across Europe

- Principle short term priority

Increase representativeness of data

- Increase coverage in individual countries

Collection of additional denominator data to adjust for sampling frequency etc.

- Via point prevalence surveys
- Challenge of additional workload for participating laboratories

Need to be able to link data from different surveillance systems

Case-based reporting for new emerging threats

# AMR surveillance priorities

## Long term

- Increase number of drug-bug combinations
  - Include non-mandatory combinations
- Inclusion of non-blood culture isolates
  - Difference in resistance rates
  - Identify most cost-effective way of collecting additional data
- Identification of clones and molecular mechanisms?
- Link to non-human AMR data
- Collaboration between different networks

**Thank you for your attention!**